Mayo Clinic’s hometown wants to be a $6.5B biotech hub

Damian Garde Rochester, MN, home of the Mayo Clinic, is an otherwise unassuming Midwestern city, housing about 111,000 people on the Zumbro River. But the town's leaders have a ...

Third Rock eyes a Cambridge, MA, beachhead as biotech gets priced out

Damian Garde As growing demand for lab space in Cambridge, MA, threatens to price out startups, biotech foundry Third Rock Ventures is looking to make a splash in the neighborhood to ...

MorphoSys bags a peptide biotech for $22M

Damian Garde MorphoSys pulled the trigger on a deal for partner Lanthio Pharma, paying €20 million ($ 22 million) for the shares it didn't already own and picking up a handful ...

Gilead jumps into epigenetics with a bite-size biotech buyout

Damian Garde As market watchers wonder whether Gilead Sciences is on the verge of a blockbuster buyout, the Big Biotech inked a small deal that will beef up its efforts in the growing ...

Atlas Venture unveils a $280M pure play biotech startup fund

John Carroll Squarely focused on seeding and nurturing biotech startups and armed with some of the best relationships in the business, Atlas Venture is unveiling a new $ 280 million ...

Plotting a course for True North, biotech CEO steps up with a $35M round

John Carroll Nancy Stagliano has a very clear idea of how to plot a course for True North. Eighteen months ago the biotech CEO raised $ 30 million for iPierian and split its assets ...

Allergy biotech hauls in $80M for its oral immunotherapy

Damian Garde Food allergy upstart Allergen Research Corporation raised an $ 80 million B round to get its lead candidate into late-stage development, pushing ahead with a treatment ...

Biotech bonanza helps Bessemer roll out a $1.6B venture fund

John Carroll Bessemer Venture Partners is rolling out a new, global fund with $ 1.6 billion to invest in a range of new technologies–including biotech. FierceBiotech News

Biotech IPOs slump as Inotek comes in low and Carbylan strikes out

Damian Garde The frothy market for biotech debuts is looking a bit less promising this week as one entrant priced well below its hoped-for range and another called off its IPO altogether. FierceBiotech ...

Novartis makes concerted push into Israeli biotech startup scene

Nick Paul Taylor Over the past year, Novartis has struck a pair of deals in Israel, snagging an option to buy Gamida Cell and a stake in BioLineRx. FierceBiotech News

Biotech boom drives blockbuster VC investments in Boston, San Francisco

John Carroll The venture boom that funneled billions of dollars into life sciences companies last year included a big surge in first-time deals, according to a fresh analysis of the ...

Drug-device biotech SteadyMed swings for a $55M IPO

Damian Garde Israel's SteadyMed is plotting to raise $ 55 million on Wall Street to support its development of a drug-device combination treatment for pulmonary arterial hypertension.  FierceBiotech ...
Page 3 of 1812345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS